2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

628. Aggressive Lymphomas: Cellular Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

5442 The impact of pre-existing comorbidity burden on outcomes after CAR T-cell therapy across hematologic malignancies - a retrospective analysis from the cwp and ctiwp of the EBMT

Silvia Escribano Serrat, MD, Fabio Andreozzi, MD2, Mouad Abouqateb3, William Boreland4, Christophe Peczynski5, Rand Fatouh6, Thomas Pabst, MD7, Peter Dreger, Prof. Dr. med.8, Christof Scheid, MD9, Anne Huynh, MD10, Raynier Devillier, PhD11, Ibrahim Yakoub-Agha12, Charles Herbaux, MD, PhD13, Victoria Potter, MBBS, BSc, FRACP, FRCPA14, Edouard Forcade, MD, PhD15, Gerald Wulf16, Georg-Nikolaus Franke Sr, MD17, Katherine Clesham18, Rachel Protheroe, MBBS, PhD19, Sridhar Chaganti, MD, PhD, FRCPath, MRCP20, Matthew Collin, Professor21, Dominik Schneidawind, MD, PhD22, Friedrich Stölzel23, Francis Ayuk24, Samar Kulkarni25, Roni Shouval Jr, MD, PhD26, Ana Alarcón Tomás27, Simona Pagliuca, MD,PhD28, Zinaida Peric29, Alberto Mussetti30, Ivan Moiseev, MD, PhD31, Hélène M Schoemans, MD, PhD32, Lars Gjaerde, MD33, Charlotte E. Graham34, Jurgen Kuball, MD35, Olaf Penack, MD, PhD36
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Universitat Autònoma de Barcelona, Barcelona, Cataluña, Spain
2 Institut Jules Bordet, Bruxelles, Belgium
3 Complications Working Party of the EBMT, Paris, France, EBMT Paris Study Unit, Paris, France
4 Complications Working Party of the EBMT, Paris, France, EBMT Paris Study Unit, Paris, France
5 Complications Working Party of the EBMT, Paris, France, EBMT Paris Study Unit, Paris, France
6 Complications Working Party of the EBMT, Paris, France, EBMT Paris Study Unit, Paris, France
7 University Hospital Bern, Bern, Switzerland
8 University of Heidelberg, Heidelberg, Germany
9 University of Cologne, Cologne, Germany
10 CHU Institut Universitaire du Cancer Toulouse, Toulouse, France
11 Programme de Transplantation & Therapie Cellulaire, Marseille, France
12 CHU de Lille, Lille, France
13 CHU Montpellier, Montpellier, France
14 Kings College Hospital London, London, United Kingdom
15 CHU Bordeaux, Hopital Haut-Leveque, Pessac, France
16 Universitaetsklinikum Goettingen, Goettingen, Germany
17 Medical Clinic and Policinic 1, Leipzig, Germany
18 University College London Hospital,, London, United Kingdom
19 University Hospitals Bristol and Weston NHSFT, Bristol, United Kingdom
20 Birmingham Centre for Cellular Therapy and Transplant (BCCTT), Birmingham, United Kingdom
21 RVI Newcastle, Newcastle, United Kingdom
22 University Hospital Zurich, Zurich, Switzerland
23 University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
24 University Hospital Eppendorf, Hamburg, Germany
25 Christie Hospital Manchester, Manchester, United Kingdom
26 Memorial Sloan Kettering Cancer Center, New York, New York, United States
27 Cellular Therapy & Immunobiology Working Party of the EBMT, Leiden, Netherlands, Hospital Puerta de Hierro, Madrid, Spain
28 Cellular Therapy & Immunobiology Working Party of the EBMT, Leiden, Netherlands, CHRU de Nancy, University of Lorraine, Nancy, France
29 Complications Working Party of the EBMT, Paris, France, Rijeka University Hospital Centre, Rijeka, Croatia
30 Complications Working Party of the EBMT, Paris, France, Institut Catalá d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain
31 Complications Working Party of the EBMT, Paris, France, RM Gorbacheva Research Institute, Pavlov University, St Petersburg, Russian Federation
32 Complications Working Party of the EBMT, Paris, France, University Hospitals Leuven & Department of Public Health and Primary Care, ACCENT VV, KU Leuven, University of Leuven, Leuven, Belgium
33 Complications Working Party of the EBMT, Paris, France, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
34 Complications Working Party of the EBMT, Paris, France, Comprehensive Cancer Center, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
35 Cellular Therapy & Immunobiology Working Party of the EBMT, Leiden, Netherlands, University Medical Centre Utrecht, Utrecht, Netherlands
36 Charité Universitätsmedizin Berlin, Department of Hematology, Oncology and Tumor immunology, Berlin, Germany
Background: Chimeric antigen receptor T-cell (CAR T-cell) therapy has transformed the treatment of hematologic malignancies, but outcomes remain heterogeneous, highlighting the need for improved risk-stratification tools. Comorbidity indices are well established in hematopoietic cell transplantation and are increasingly applied to CAR T-cell therapy, yet their prognostic utility across disease indications remains uncertain. We therefore evaluated the performance of the Cellular Therapy–Comorbidity Index (CT-CI) and Hematopoietic Cell Transplantation–Comorbidity Index (HCT-CI) for overall survival (OS) and non-relapse mortality (NRM) across B-cell lymphoma (BCL) and multiple myeloma (MM) in a large EBMT registry cohort.

Methods: This retrospective EBMT registry study included adults receiving commercial CAR T-cell therapy for BCL or MM between January 2019-June 2024. CT-CI and HCT-CI were categorized as 0, 1–2, and ≥3. OS and progression-free survival (PFS) were estimated by Kaplan–Meier, and NRM and relapse/progression incidence (RI) by competing-risk cumulative incidence. Separate multivariable Cox models for OS and cause-specific NRM were fitted for each score and adjusted for age and prior auto-HCT, with robust standard errors accounting for center effect, and baseline hazards stratified by disease–product combination. Score-by-disease interactions assessed heterogeneity in hazard ratios across diseases. Incremental discrimination beyond the adjustment variables was assessed using Harrell’s C-index.

Results: A total of 6,095 patients were included. Median age was 62.9 years (IQR, 54.3–70.1), 37% were female and ECOG performance status was 0–1 in 93%. The cohort included 4,927 patients (89%) with BCL, including 484 (8%) with mantle cell lymphoma (MCL), and 684 (11%) with MM. Median diagnosis-to-infusion was 1.5 years (IQR, 0.9–4.3), and 29% received prior auto-HCT. Products included axi-cel (57%) and tisa-cel (21%), followed by ide-cel (9%), brexu-cel (8%), cilta-cel (3%), and liso-cel (2%).

At 2.0-year median follow-up, the 2-year OS and PFS estimates were 56.3% (95% CI, 54.9–57.7) and 41.3% (95% CI, 39.9–42.7), while NRM and RI were 8.9% (95% CI, 8.1–9.8) and 49.7% (95% CI, 48.3–51.1). Unadjusted outcomes worsened numerically with increasing comorbidity burden. Two-year OS declined across CT-CI categories 0, 1–2, and ≥3 from 59.5% to 50.1% and 38.7%; corresponding HCT-CI estimates were 59.1%, 57.0%, and 49.7%. Two-year NRM increased from 8.1% to 10.6% and 13.9% across CT-CI categories and from 6.8% to 8.5% and 13.7% across HCT-CI categories.

In adjusted multivariable models, higher CT-CI and HCT-CI were associated with worse OS. Compared with CT-CI 0, aHRs for CT-CI 1–2 and ≥3 were 1.35 (95% CI, 1.23–1.48) and 2.12 (95% CI, 1.71–2.61); corresponding HCT-CI aHRs were 1.13 (95% CI, 1.00–1.26) and 1.31 (95% CI, 1.17–1.47). For NRM, CT-CI 1–2 and ≥3 had aHRs of 1.37 (95% CI, 1.14–1.64) and 2.29 (95% CI, 1.53–3.44). For HCT-CI, only ≥3 was associated with increased NRM (aHR, 1.84; 95% CI, 1.52–2.23).

No significant heterogeneity across disease groups was observed for the association of either score with OS or for CT-CI with NRM. In contrast, the association between HCT-CI and NRM varied by disease (interaction p=0.006). HCT-CI ≥3 was associated with higher NRM in BCL (aHR, 1.93; 95% CI, 1.57–2.37) and MM (aHR, 3.29; 95% CI, 1.72–6.30), whereas no significant association was observed in MCL (aHR, 1.02; 95% CI, 0.59–1.75).

For OS, CT-CI provided significantly greater discrimination than HCT-CI (C-index, 0.564 vs 0.549; Δ, 0.015; 95% CI, 0.006–0.024). For NRM, both scores modestly improved discrimination over the baseline model; HCT-CI was numerically higher than CT-CI (0.619 vs 0.606), although the difference was not significant (Δ, −0.013; 95% CI, −0.031 to 0.006). In disease specific analyses, incremental discrimination was clearest in BCL, imprecise in MM, and minimal in MCL.

Conclusions: Comorbidity burden provides incremental prognostic information for OS and NRM after CAR T-cell therapy, although the overall discriminatory performance of both CT-CI and HCT-CI was modest. CT-CI showed stronger associations with OS, whereas the performance of HCT-CI for NRM varied across disease indications. These findings support the inclusion of structured comorbidity assessment in the evaluation of CAR T-cell candidates, while underscoring the need for further refinement and disease-specific validation of CAR T-cell–adapted risk models.
Silvia Escribano Serrat, MD: Alfonso Martín Escudero Foundation - Research Funding; Alfonso Martín Escudero Foundation - Research Funding